Having trouble accessing articles? Reset your cache.

Lilly bolsters atopic dermatitis arsenal via $1.1B Dermira deal, gaining Dupixent challenger

Via its $1.1 billion takeout of Dermira on Friday, Eli Lilly added to its late-stage pipeline an atopic dermatitis therapy that could challenge Dupixent.

The price -- $18.75 per share -- is a premium of only 2% to Thursday’s close of $18.34, but the deal comes during a week when Dermira Inc. (NASDAQ:DERM) shares added $200 million

Read the full word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers